CareDx Stock Soars 24% as Testing Revenue Jumps 65% and Transplant Test Maker Lifts 2026 Sales Outlook
CareDx shares rose 24% after reporting Q3 revenue of $139M, up 39%, and raising its 2026 outlook. Testing services revenue grew 65%, and the company plans new tests for 2027. Net income was $19M, with adjusted EBITDA at $30M. The stock has gained 377% over 52 weeks.
How this was made
The 30-second read
Why it matters
The stock reaction is tied to a fresh earnings print with multiple beats (revenue, testing services, EBITDA margin) plus explicit 2026 forecast increases and concrete 2027 product plans, which can change both near-term expectations and longer-dated growth assumptions.
Market read
Traders can reprice the stock immediately based on the company’s raised 2026 revenue and adjusted EBITDA ranges, alongside evidence of accelerating test volume and improving margins.
What to watch
Execution risk remains around integrating Naveris, sustaining test volume growth, and achieving lab readiness for 2027 launches by end-2026.
Background
CareDx is a transplant diagnostics company that expanded into specialty oncology via its July 1 acquisition of Naveris (NavDx). The article frames a turnaround from prior reimbursement and billing concerns.
Market effects
Supports the transplant and specialty oncology diagnostics theme, potentially improving sentiment toward cash-generative, test-volume-driven healthcare tools.
Primarily US-listed single-name impact; limited direct regional spillover beyond healthcare diagnostics sentiment.
Moderate global relevance via oncology monitoring and transplant diagnostics demand signals, but no cross-border policy or supply shock mentioned.
Counterpoint
The guidance raise may already embed optimistic assumptions on NavDx pricing appreciation and oncology scaling, leaving less room for upside if pricing or volume growth normalizes.
Key entities
- companyCareDx
Transplant and specialty oncology diagnostics company reporting Q3 results, raising 2026 guidance, and outlining 2027 test launches.
- companyNaveris
Acquired July 1, contributing specialty oncology test volume and revenue in the first full quarter.
- productNavDx
Blood test for monitoring HPV-related head and neck cancers; pricing appreciation expectations are cited.
- productAlloHeme
Blood test targeting relapse detection after cell therapy in AML and MDS; median lead time cited.
- productHistoMap Kidney
Tissue-based test to classify kidney transplant rejection types; lab readiness targeted by end-2026.
